UF Center for Movement Disorders and Neurorestoration
Welcome,         Profile    Billing    Logout  
 15 Trials 
16 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Okun, Michael S
NCT02056873: Tourette Syndrome Deep Brain Stimulation

Completed
N/A
10
US
Continuous DBS, Neurostimulator: Medtronic Activa PC+S Device Model 37604, CM thalamic leads: Medtronic Leads Model 3387, ECOG strip leads: The Resume II Medtronic Model 3587A, Responsive Brain Stimulation (RBS Setting)
University of Florida, Medtronic, National Institute of Neurological Disorders and Stroke (NINDS)
Tourette Syndrome
08/21
08/23
Foote, Kelly
NCT03622905: ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

Completed
N/A
74
Europe, Canada, US
DBS-f On, DBS Off
Functional Neuromodulation Ltd
Alzheimer Disease
02/24
02/24
Rodriguez, Ramon
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
10/24
10/24
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Active, not recruiting
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
10/24
02/25
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
Malaty, Irene A
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Active, not recruiting
3
196
Europe, Canada, US, RoW
Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Disorder
12/24
12/24
McFarland, Nikolaus
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Recruiting
2
80
US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
CT-AMT-130-01, NCT04120493: Safety and Proof-of-Concept (POC) Study with AMT-130 in Adults with Early Manifest Huntington's Disease

Hourglass Jan 2021 - Dec 2021 : Early efficacy data on initial patients for Huntington's disease
Checkmark First biomarker data from trial for Huntington’s disease
Nov 2021 - Nov 2021: First biomarker data from trial for Huntington’s disease
Checkmark Safety data from P1/2 trial for Huntington’s disease
Feb 2021 - Feb 2021: Safety data from P1/2 trial for Huntington’s disease
Recruiting
1/2
37
US
intra-striatal rAAV5-miHTT, AMT-130, Imitation (sham) surgery
UniQure Biopharma B.V.
Huntington's Disease
04/29
06/29
Deeb, Wissam
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Recruiting
3
150
Europe, Canada, US, RoW
Ecopipam, Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Syndrome
11/24
03/27
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Active, not recruiting
3
196
Europe, Canada, US, RoW
Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Disorder
12/24
12/24
Segura, Julie
POPLAR-NF2, NCT05130866: Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Recruiting
2/3
92
US
REC-2282, AR-42, OSU-HDAC42, NSC-D736012, Placebo
Recursion Pharmaceuticals Inc.
Neurofibromatosis Type 2
01/27
07/27
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Completed
2
199
US
NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel
NFlection Therapeutics, Inc.
Cutaneous Neurofibroma, Neurofibromatosis 1
10/23
10/23
MOVE FSHD, NCT04635891: Motor Outcomes to Validate Evaluations in FSHD

Recruiting
N/A
450
Europe, Canada, US
University of Kansas Medical Center, FSHD Society, Inc., Friends Research Institute, Inc., University of Rochester, University of Nevada, Reno, FSHD Canada, Avidity Biosciences, Inc., AMRA Medical, Seattle Children's Hospital, Dyne Therapeutics, Hoffmann-La Roche
FSHD
12/26
01/27

Download Options